Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.

MLA

Sanglier, Thibaut, et al. “Trastuzumab Emtansine vs Lapatinib and Capecitabine in HER2-Positive Metastatic Breast Cancer Brain Metastases: A Real-World Study.” Breast, vol. 69, June 2023, pp. 441–50. EBSCOhost, https://doi.org/10.1016/j.breast.2023.01.007.

APA

Sanglier, T., Shim, J., Lamarre, N., Peña-Murillo, C., Antao, V., & Montemurro, F. (2023). Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. Breast, 69, 441–450. https://doi.org/10.1016/j.breast.2023.01.007

Chicago

Sanglier, Thibaut, Jinjoo Shim, Neil Lamarre, Claudia Peña-Murillo, Vincent Antao, and Filippo Montemurro. 2023. “Trastuzumab Emtansine vs Lapatinib and Capecitabine in HER2-Positive Metastatic Breast Cancer Brain Metastases: A Real-World Study.” Breast 69 (June): 441–50. doi:10.1016/j.breast.2023.01.007.